ArticleCancer medicine2023

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer.

Zhuo-Miao Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.